Peregrine Clarifies Its Anti-Angiogenesis VEGF Antibody and Vascular Targeting Agents Compared to Other VEGF Antibodies

Avid Bioservices Signs Manufacturing Supply Agreement For The Production Of Four Monoclonal Antibodies

Peregrine Pharmaceuticals Announces Grant of Patent For Vasopermeation Enhancing Agents

Peregrine Names Steven King As President And Chief Executive Officer

Avid Bioservices and Inhibitex Finalize Supply Agreement for Additional cGMP Manufacturing Runs

Overview of First International Conference on Vascular Targeting Published in Cancer Research

Peregrine Announces Quarterly Conference Call

Peregrine Pharmaceuticals Announces Grant Of Patent For New Anti-Angiogenic Treatments

Peregrine Pharmaceuticals Receives FDA Approval for its Cotara(TM) Phase III Registration Trial Design for Brain Cancer

Peregrine Pharmaceuticals Receives Additional 180-Day Grace Period from Nasdaq